Pancreatic Cancer Research

ResearcherDuke UniversityActive in the last 2 years

Niharika B. Mettu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7821-3298; OpenAlex author ID A5072094247. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 7

  1. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  2. Exploratory analysis of mesenteric-portal axis CT radiomic features for survival prediction of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-023-09532-0↗
  3. Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS G12R-mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10637-020-01044-8↗
  4. CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Co-author DOI 10.1148/radiol.2021210699↗
  5. A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis. Co-author DOI 10.21037/acr-20-154↗
  6. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Co-author DOI 10.1136/jitc-2020-000587↗
  7. Clinical Insights Into the Biology and Treatment of Pancreatic Cancer. Co-author DOI 10.1200/jop.2015.009092↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peijie Lyu · 2 shared papers, 2021–2023 · strength 0.28
  2. Desiree E. Morgan · 2 shared papers, 2021–2023 · strength 0.28
  3. Francesca Rigiroli · 2 shared papers, 2021–2023 · strength 0.28
  4. Daniele Marin · 2 shared papers, 2021–2023 · strength 0.28
  5. Michael James Overman · 2 shared papers, 2020–2024 · strength 0.25
  6. James L. Abbruzzese · 2 shared papers, 2016–2021 · strength 0.24
  7. Nick Pavlakis · 1 shared paper, 2024 · strength 0.16
  8. Mariano Ponz‐Sarvisé · 1 shared paper, 2024 · strength 0.16
  9. Adnan M. Nagrial · 1 shared paper, 2024 · strength 0.16
  10. David Robert Spigel · 1 shared paper, 2024 · strength 0.16
  11. Andrew L. Coveler · 1 shared paper, 2024 · strength 0.16
  12. Matthew J. Reilley · 1 shared paper, 2024 · strength 0.16
  13. Mark M. Zalupski · 1 shared paper, 2024 · strength 0.16
  14. Christos K Fountzilas · 1 shared paper, 2024 · strength 0.16
  15. Anne M. Noonan · 1 shared paper, 2024 · strength 0.16
  16. Wells A. Messersmith · 1 shared paper, 2024 · strength 0.16
  17. Nataliya Volodymyrivna Uboha · 1 shared paper, 2024 · strength 0.16
  18. Teresa Mercade Macarulla · 1 shared paper, 2024 · strength 0.16
  19. Cara M. Kenney · 1 shared paper, 2021 · strength 0.13
  20. Edward Jae-Hoon Kim · 1 shared paper, 2021 · strength 0.13
  21. Udo Rudloff · 1 shared paper, 2021 · strength 0.13
  22. Nicholas C. DeVito · 1 shared paper, 2021 · strength 0.12
  23. John H. Strickler · 1 shared paper, 2021 · strength 0.12
  24. Hope Elizabeth Uronis · 1 shared paper, 2021 · strength 0.12
  25. Sabino Zani · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.